CoChat

Transplantation of human induced pluripotent stem cell-derived cardiomyocytes improves myocardial function and reverses ventricular remodeling in infarcted rat hearts

Open access

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) have shed great light on cardiac regenerative medicine and specifically myocardial repair in heart failure patients. However, the treatment efficacy and the survival of iPSC-CMs in vivo after transplantation have yielded inconsistent results. OBJECTIVES: The objective of this study was to evaluate the ability of human iPSC-CMs to improve myocardial function in a rat postinfarction heart failure model. METHODS: human iPSC-CMs 10 days after undergoing left anterior descending (LAD) coronary artery ligation. Cyclosporine A and methylprednisolone were administered before iPSC-CM injection and until the rats were killed to prevent graft rejection. Cardiac function was evaluated by echocardiography. The survival of grafted cardiomyocytes was confirmed by observing the fluorescent cell tracer Vybrant™ CM-DiI or expression of the enhanced green fluorescent protein (eGFP) in transplanted cells, or survival was demonstrated by polymerase chain reaction (PCR)-based detection of human mitochondrial DNA. Sirius red stain was used to evaluate the fibrosis ratio. Hematoxylin-eosin staining was used to observe the formation of teratomas. RESULTS: Four weeks after intramyocardial injection of iPSC-CMs, animals undergoing iPSC-CM transplantation had lower mortality than the control group. Animals injected with cell-free solution (control group) demonstrated significant left ventricular (LV) functional deterioration, whereas grafting of iPSC-CMs attenuated this remodeling process. In the control group, the ejection fraction deteriorated by 10.11% (from 46.36 to 41.67%), and fractional shortening deteriorated by 9.23% (from 24.37 to 22.12%) by 4 weeks. In the iPSC-CM injection group, the ejection fraction improved by 18.86% (from 44.09 to 52.41%), and fractional shortening improved by 23.69% (from 23.08 to 28.54%). Cell labeling, tracking, and molecular biology techniques indicated that the grafted cardiomyocytes survived in the rat heart 1 month after iPSC-CM transplantation. Myocardial fibrosis was also attenuated in the iPSC-CM treatment group. CONCLUSIONS: Human iPSC-CM grafts survived in infarcted rat hearts and restored myocardial function 4 weeks after transplantation. Cell replacement therapy also reversed ventricular remodeling, indicating the potential of iPSC-CMs for cardiac repair strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13287-020-01602-0

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Left ventricular function following human iPSC-CM therapy. a Representative images of hearts at baseline (before MI model established), D0 (10 days after LAD coronary artery ligation and before iPSC-CM grafting) and D28 (4 weeks after iPSC-CM grafting) with administration of 5% albumin solution (CTL group) (upper) versus iPSC-CMs (iPS-CM group) (lower). b Quantification of left ventricular ejection fraction (EF) and change of EF (D28-D0/D0) demonstrated a trend toward improved functional recovery at 4 weeks after the second thoracotomy in the iPS-CM group compared with the CTL group. c Quantification of left ventricular fractional shortening (FS) and change of FS (D28-D0/D0) demonstrated a trend toward improved functional recovery at 4 weeks after the second thoracotomy in the iPS-CM group compared with the CTL group. d–i Quantification of left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV), end-systolic and end-diastolic left ventricular anterior wall (LVAW) thickness and changes in these indicators. iPSC-CMs induced pluripotent stem cell-derived cardiomyocytes, MI myocardial infarction, LAD left anterior descending, CTL control, LVAW(s) left ventricular anterior wall thickness (end-systolic), LVAW(d) left ventricular anterior wall thickness (end-diastolic). (CTL group: n = 8; iPS-CM group: n = 9). Unpaired two-tailed t-test with * vs CTL P < 0.05, n.s. = not significant
Fig. 1 Left ventricular function following human iPSC-CM therapy. a Representative images of hearts at baseline (before MI model established), D0 (10 days after LAD coronary artery ligation and before iPSC-CM grafting) and D28 (4 weeks after iPSC-CM grafting) with administration of 5% albumin solution (CTL group) (upper) versus iPSC-CMs (iPS-CM group) (lower). b Quantification of left ventricular ejection fraction (EF) and change of EF (D28-D0/D0) demonstrated a trend toward improved functional recovery at 4 weeks after the second thoracotomy in the iPS-CM group compared with the CTL group. c Quantification of left ventricular fractional shortening (FS) and change of FS (D28-D0/D0) demonstrated a trend toward improved functional recovery at 4 weeks after the second thoracotomy in the iPS-CM group compared with the CTL group. d–i Quantification of left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV), end-systolic and end-diastolic left ventricular anterior wall (LVAW) thickness and changes in these indicators. iPSC-CMs induced pluripotent stem cell-derived cardiomyocytes, MI myocardial infarction, LAD left anterior descending, CTL control, LVAW(s) left ventricular anterior wall thickness (end-systolic), LVAW(d) left ventricular anterior wall thickness (end-diastolic). (CTL group: n = 8; iPS-CM group: n = 9). Unpaired two-tailed t-test with * vs CTL P < 0.05, n.s. = not significantCC BY · PubMed Central
Fig. 2 Electrocardiogram (ECG) for rats during establishment of the myocardial infarction (MI) model and 28 days after iPSC-CM therapy. Representative traces from rat ECG recordings are shown (a, b). Readings are normal at baseline before left anterior descending (LAD) coronary artery ligation in the CTL group and iPS-CM group. c, d ST segment elevation in every group after LAD coronary artery ligation, which indicated that the MI model was successful. e, f No ventricular arrhythmias occurred 28 days after iPSC-CM transplantation. CTL control, iPSC-CMs induced pluripotent stem cell-derived cardiomyocytes
Fig. 2 Electrocardiogram (ECG) for rats during establishment of the myocardial infarction (MI) model and 28 days after iPSC-CM therapy. Representative traces from rat ECG recordings are shown (a, b). Readings are normal at baseline before left anterior descending (LAD) coronary artery ligation in the CTL group and iPS-CM group. c, d ST segment elevation in every group after LAD coronary artery ligation, which indicated that the MI model was successful. e, f No ventricular arrhythmias occurred 28 days after iPSC-CM transplantation. CTL control, iPSC-CMs induced pluripotent stem cell-derived cardiomyocytesCC BY · PubMed Central
Fig. 3 Detection of human cells within rat hearts and other organs by polymerase chain reaction (PCR) of human mitochondria DNA at different timepoints after cell transplantation. a PCR of human mitochondrial DNA in the heart and other organs of rats at 28 days after cell transplantation in the CTL group (n = 2) and iPS-CM group (n = 4). b PCR of human mitochondrial DNA in the heart and other organs of rats at 24 h after cell transplantation in the iPS-CM group (n = 3). c PCR of human mitochondrial DNA in the heart and other organs of rats at 7 days after cell transplantation in the iPS-CM group (n = 3). (+) indicates positive control with iPSC-CMs. (−) indicates a negative control with DEPC water. CTL control, iPSC-CMs induced pluripotent stem cell-derived cardiomyocytes
Fig. 3 Detection of human cells within rat hearts and other organs by polymerase chain reaction (PCR) of human mitochondria DNA at different timepoints after cell transplantation. a PCR of human mitochondrial DNA in the heart and other organs of rats at 28 days after cell transplantation in the CTL group (n = 2) and iPS-CM group (n = 4). b PCR of human mitochondrial DNA in the heart and other organs of rats at 24 h after cell transplantation in the iPS-CM group (n = 3). c PCR of human mitochondrial DNA in the heart and other organs of rats at 7 days after cell transplantation in the iPS-CM group (n = 3). (+) indicates positive control with iPSC-CMs. (−) indicates a negative control with DEPC water. CTL control, iPSC-CMs induced pluripotent stem cell-derived cardiomyocytesCC BY · PubMed Central
Fig. 4 Quantitative polymerase chain reaction (qPCR) quantification of human mitochondrial DNA confirms the presence of human cells within rat hearts but not other organs 4 weeks after cell transplantation. a Plot of SYBR-based human mitochondrial DNA quantification demonstrated human cell distribution in each organ of rats in the CTL group. b Plot of SYBR-based human mitochondrial DNA quantification demonstrated human cell distribution in each organ of the iPS-CM group. Cardiomyocytes were used as a positive control. c qPCR quantification analysis of human mitochondria DNA demonstrated that human cells survived in rat hearts but not in other organs in the iPS-CM group (vs control group at 4 weeks following iPSC-CM transplantation) (n = 3 per group). CTL control, iPSC-CMs induced pluripotent stem cell-derived cardiomyocytes. Unpaired two-tailed t-test with * vs CTL P < 0.05, *** vs CTL P < 0.005, n.s. = not significant
Fig. 4 Quantitative polymerase chain reaction (qPCR) quantification of human mitochondrial DNA confirms the presence of human cells within rat hearts but not other organs 4 weeks after cell transplantation. a Plot of SYBR-based human mitochondrial DNA quantification demonstrated human cell distribution in each organ of rats in the CTL group. b Plot of SYBR-based human mitochondrial DNA quantification demonstrated human cell distribution in each organ of the iPS-CM group. Cardiomyocytes were used as a positive control. c qPCR quantification analysis of human mitochondria DNA demonstrated that human cells survived in rat hearts but not in other organs in the iPS-CM group (vs control group at 4 weeks following iPSC-CM transplantation) (n = 3 per group). CTL control, iPSC-CMs induced pluripotent stem cell-derived cardiomyocytes. Unpaired two-tailed t-test with * vs CTL P < 0.05, *** vs CTL P < 0.005, n.s. = not significantCC BY · PubMed Central
Fig. 5 Histological evaluation confirms iPSC-CM homing to the infarcted heart. a–c The grafted cells were labeled with the fluorescent cell tracer Vybrant™ CM-DiI Cell-Labeling Solution (Molecular Probes, Invitrogen) and cultured in vitro for 2 days (a), 11 days (b), and 28 days (c). d, e Immunofluorescent staining shows alpha-actinin (green) in rat heart tissue; the grafted cells were prelabeled with Vybrant- CM-DiI (Red) and detected under a microscope 7 days after transplantation. f iPSC-CMs were detected by eGFP immunofluorescent staining 4 weeks after transplantation. iPSC-CMs induced pluripotent stem cell-derived cardiomyocytes, and eGFP enhanced green fluorescent protein
Fig. 5 Histological evaluation confirms iPSC-CM homing to the infarcted heart. a–c The grafted cells were labeled with the fluorescent cell tracer Vybrant™ CM-DiI Cell-Labeling Solution (Molecular Probes, Invitrogen) and cultured in vitro for 2 days (a), 11 days (b), and 28 days (c). d, e Immunofluorescent staining shows alpha-actinin (green) in rat heart tissue; the grafted cells were prelabeled with Vybrant- CM-DiI (Red) and detected under a microscope 7 days after transplantation. f iPSC-CMs were detected by eGFP immunofluorescent staining 4 weeks after transplantation. iPSC-CMs induced pluripotent stem cell-derived cardiomyocytes, and eGFP enhanced green fluorescent proteinCC BY · PubMed Central
Fig. 6 Sirius red staining to identify fibrosis. a Sirius red staining of cardiac sections 4 weeks after cell transplantation. Collagen fibers stain red, and cardiac muscle fibers stain yellow. b Quantification of fibrosis demonstrated that iPSC-CM therapy tended to reduce the amount of fibrosis compared with the CTL group, but there was no significant difference. CTL control, iPSC-CMs induced pluripotent stem cell-derived cardiomyocytes (CTL group: n = 5; iPS-CM group: n = 6). Unpaired two-tailed t-test, n.s. = not significant
Fig. 6 Sirius red staining to identify fibrosis. a Sirius red staining of cardiac sections 4 weeks after cell transplantation. Collagen fibers stain red, and cardiac muscle fibers stain yellow. b Quantification of fibrosis demonstrated that iPSC-CM therapy tended to reduce the amount of fibrosis compared with the CTL group, but there was no significant difference. CTL control, iPSC-CMs induced pluripotent stem cell-derived cardiomyocytes (CTL group: n = 5; iPS-CM group: n = 6). Unpaired two-tailed t-test, n.s. = not significantCC BY · PubMed Central
Fig. 7 Tumorigenicity was evaluated by subcutaneous injection of 1 × 107 iPSC-CMs in nude mice. a Thirteen Nude mice were injected with 1 × 107 iPSC-CMs and did not develop tumors. b Twelve nude mice were injected with Hela cells (1 × 107) and were used as positive control group, which developed tumor at the site of injection. c, d Hematoxylin-eosin staining of the injected site in iPS-CM group (c) and positive control group (d)
Fig. 7 Tumorigenicity was evaluated by subcutaneous injection of 1 × 107 iPSC-CMs in nude mice. a Thirteen Nude mice were injected with 1 × 107 iPSC-CMs and did not develop tumors. b Twelve nude mice were injected with Hela cells (1 × 107) and were used as positive control group, which developed tumor at the site of injection. c, d Hematoxylin-eosin staining of the injected site in iPS-CM group (c) and positive control group (d)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 94

Metadata

Authors
Guan, X., Xu, W., Zhang, H., Wang, Q., Yu, J., Zhang, R., Chen, Y., Xia, Y., Wang, J., & Wang, D.
Affiliations
  • First Affiliated Hospital of Dalian Medical University (CN)
  • Nanjing University of Chinese Medicine (CN)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • HELP Therapeutics (China) (CN)
  • Jiangsu Province Hospital (CN)
  • Nanjing Drum Tower Hospital (CN)
Corresponding author
  • Wang, Jiaxian
  • Wang, Dongjin
Venue
Stem Cell Research & Therapy
Published
2020-02-21
Volume
11
Issue
1
Pages
201-201
ISSN
1757-6512 (ISSN-L)
OpenAlex
W3012728641
Cited by
91
References
32
Citations by year
2026: 8 · 2025: 14 · 2024: 12 · 2023: 19 · 2022: 17 · 2021: 15 · 2020: 6
FWCI
4.62
Type
journal article
Language
en
Open access
Licence
Locations
  • Stem Cell Research & Therapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Outstanding Youth Science Fund Project of National Natural Science Foundation of China (81900253)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
Keywords
iPSC-derived cardiomyocytes, cell transplantation, myocardial infarction, ventricular remodeling, heart failure, graft survival, myocardial fibrosis, intramyocardial injection, graft rejection prevention, cyclosporine, methylprednisolone, teratoma formation, cardiac regeneration, ejection fraction, rat model, cell tracking, mitochondrial DNA
MeSH terms
Animals, Cell Differentiation, Disease Models, Animal, Humans, Male, Myocardial Infarction, Rats, Sprague-Dawley, Ventricular Remodeling, Myocytes, Cardiac, Stem Cell Transplantation, Regenerative Medicine, Rats, Induced Pluripotent Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Transplantation of human induced pluripotent stem cell-derived cardiomyocytes improves myocardial function and reverses ventricular remodeling in infarcted rat hearts. https://app.cochat.ai/papers/10.1186/s13287-020-01602-0
The paper
Guan, X., Xu, W., Zhang, H., Wang, Q., Yu, J., Zhang, R., Chen, Y., Xia, Y., Wang, J., & Wang, D. (2020). Transplantation of human induced pluripotent stem cell-derived cardiomyocytes improves myocardial function and reverses ventricular remodeling in infarcted rat hearts. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-020-01602-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.